Products from BPS Bioscience require a minimum order value above 400€
Application: Screen IL-33 antibodies.
Background: Interleukin-33 (IL-33) is a tissue-derived alarmin cytokine belonging to the Interleukin-1 (IL-1) family that regulates tissue homeostasis and inflammation and plays a key role in allergic airway diseases. IL-33 is produced constitutively by a variety of cell types, including fibroblasts, endothelial and epithelial cells, where it is stored in the cell nucleus and subsequently released in response to cell necrosis, cellular damage, stress, and tissue injury. After release, IL-33 primarily drives type 2 immune responses by activating TH2 (T helper 2) cells, mast cells, and innate lymphoid cells (ILC2s). IL-33 signals through ST2 (receptor serum-stimulated 2), also known as IL-1RL1, and its co-receptor IL-1RAcP, and activates downstream signaling pathways including NF-κB and MAPK (mitogen-activated protein kinase), leading to the production and release of pro-inflammatory cytokines. IL-33 is a promising therapeutic target for inflammatory diseases including asthma and COPD (chronic obstructive pulmonary disease), with anti-IL-33 neutralizing antibodies (including Tozorakimab) currently undergoing clinical trials.
Description: The IL-33 Responsive Luciferase Reporter Jurkat Cell Line is a Jurkat cell line engineered to express both human IL33Ra (IL-33 receptor alpha) (NM_016232.5) and human IL1RAP (IL-1 Receptor Accessory Protein) (NM_002182.4) separated by a self-cleaving P2A peptide. The construct was delivered by lentiviral transduction of NF-κB Luciferase Reporter Jurkat Cells (#60651), which express a firefly luciferase reporter driven by NF-κB (nuclear factor Kappa B) response elements located upstream of the minimal TATA promoter. After activation by IL-33, the endogenous transcription factor NF-κB binds to the response elements, inducing transcription of the luciferase reporter gene.This cell line has been validated to respond to IL-33. Figure 1: Illustration of the mechanism of IL-33 Luciferase Reporter Jurkat Cell Line. IL-33 binds to its cognate receptor to activate downstream signal pathways that converge on transcription factor NF-κB, which translocates into the nucleus where it can activate the transcription of the Firefly luciferase reporter driven by NF-κB response elements present in the promoter.Interested in having us perform the screening and profiling of inhibitors or blocking antibodies? Visit our Immunotherapy Biochemical Screening Services.
Genbank: NM_016232.5
Host Cell Line: Jurkat (clone E6-1), human T lymphoblast, suspension.
Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.
Supplied As: Each vial contains ≥1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience, #79796)
Target: IL-33
Uniprot: Q5RDG8
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1
References: Cayrol C., et al., 2018 Immunol Rev. 281(1):154-168.Drake L., et al., 2017 Immunol Rev. 278(1):173-184.England E., et al., 2023 Scientific reports. 13(1):9825.Zhou Y., et al., 2023 J Transl Med. 21(1):902.
English
Deutsch
